NeuPharma Starts Phase II Trial of Novel Treatment for Glioblastoma Multiforme

NeuPharma of Suzhou BioBay has started a Phase II trial RX108 in patients with recurrent glioblastoma multiforme (GBM). Two weeks ago, the company began a similar trial of the same candidate in patients with head and neck squamous cell carcinoma (HNSCC). RX108 is a novel small-molecule inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase). It is currently being tested in several clinical trials in China and the US for various types of cancer. More details.... Share this with colleagues: // //